Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 36, Issue 6, 2005, Pages 1450-1458

  Tseng, H F ^a   Tan, H F ^a   Chang, C K ^b  

^a CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY OF SPORT   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645035025     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bernstein HH, Rothstein EP, Watson BM, et al. Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka/Merck varicella vaccine. Pediatrics 1993; 92: 833-7.
2. Beutels P, Clara R, Tormans G, Van Doorslaer E, Van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis 1996; 174 (suppl 3): 335s-41s.
3. Boelle PY, Hanslik T. Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 2002; 129: 599-606.
4. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127: 305-14.
5. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20: 1113-25.
6. Center for Disease Control. Prevention of varicella. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45: RR-11.
7. Center for Disease Control: Prevention of Varicella. MMWR Morb Mortal Wkly Rep 1999; 48: 1-6.
8. Choo PW, Donhue JG, Manson JAE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995; 172: 706-12.
9. Clements DA, Zaref JI, Bland CL, Walter EB, Coplan PM. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Arch Pediatr Adolesc Med 2001; 155: 455-61.
10. Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17: 142-51.
11. Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 1999; 17: 1306-11.
12. Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002; 44: 211-9.
13. Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications from modelling studies. Epidemiol Infect 2001; 125: 635-50.
14. Fairley CK, Miller E. Varicella-zoster virus epidemiology: a changing scene? J Infect Dis 1996; 174 (suppl 3): S314-9.
15. Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. Age-specific incidence of chickenpox. Pubic Health Rep 1994; 109: 750-5.
16. Gershon AA, Takahashi M, White CJ. Varicella vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. Philadephia: Saunders, 1999: 475-507.
17. Getsios D, Caro JJ, Caro G, et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J 2002; 21: 542-7.
18. Guess HA, Broughton DD, Melton LJ, Kurland LT. Population based studies of varicella complications. Pediatrics 1986; 78 (suppl): 723-7.
19. Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United Sates. Am J Epidemiol 1994; 140: 81-104.
20. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J Pediatr 1994; 124: 869-74.
21. Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994 2; 271: 375-81.
22. Lin YJ, Huang LM, Lee CY, et al. A seroepidemiological study of varicella-zoster virus in Taipei city. Acta Paediatr Sin 1996; 37: 11-5.
23. Lokeshwar MR, Agrawal A, Subbararo SD, et al. Age related seroprevalence of antibodies to varicella in India. Indian Pediatr 2000; 37: 714-9.
24. Meyer PA, Seward JF, Jumman AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000; 182: 383-90.
25. Ooi PI, Goh KT, Doraising S, Ling AE. The prevalence of varicella-zoster infection in Singapore. Southeast Asian J Trop Med Public Health 1992; 23: 22-5.
26. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J 1985; 61 (suppl 4): 17-22.
27. Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunization schidule. Soc Sci Med 1999; 49: 763-79.
28. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 2000; 18: 407-15.
29. Seward J, Watson B, Peterson C, et al. Varicella disease after introduction of varicella vaccine in the Unite States, 1995-2000. JAMA 2002; 287: 606-11.
30. Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes. Pharmacoeconomics 2003; 21: 13-38.
31. Tseng HF, Tan HF, Chang CK. Varicella vaccine safety, incidence of breakthrough, and factors associated with breakthrough in Taiwan. Am J Infect Control 2003; 31: 151-6.
32. rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1993.
33. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344: 955-60.
34. Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am 1996; 10: 571-81.
35. Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr 1997; 130: 759-65.